News coverage about Neuralstem (NASDAQ:CUR) has been trending positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neuralstem earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.801474948829 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Neuralstem (NASDAQ:CUR) traded down 1.11% on Thursday, reaching $5.35. The company’s stock had a trading volume of 38,857 shares. The stock’s market cap is $63.66 million. Neuralstem has a 12 month low of $2.47 and a 12 month high of $6.60. The firm’s 50-day moving average price is $5.46 and its 200-day moving average price is $4.54.

Separately, ValuEngine raised Neuralstem from a “sell” rating to a “hold” rating in a research note on Friday, June 9th.

ILLEGAL ACTIVITY WARNING: “Favorable News Coverage Somewhat Unlikely to Impact Neuralstem (CUR) Share Price” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/07/20/favorable-news-coverage-somewhat-unlikely-to-impact-neuralstem-cur-share-price.html.

In other Neuralstem news, CEO Richard J. Daly purchased 7,500 shares of the company’s stock in a transaction dated Wednesday, May 17th. The stock was purchased at an average price of $4.00 per share, for a total transaction of $30,000.00. Following the transaction, the chief executive officer now owns 23,312 shares in the company, valued at approximately $93,248. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 19.25% of the company’s stock.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Insider Buying and Selling by Quarter for Neuralstem (NASDAQ:CUR)

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.